# US 10,117,880 B2 · Neridronic acid for treating complex regional pain syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,117,880 B2
- Document ID: US10117880B2
- Status: Granted
- Kind: B2
- Application number: 15/963,878
- Filed: 2018-04-26
- Published: 2018-08-30
- Granted: 2018-11-06
- Earliest claimed: 2012-05-14
- Assignees: Antecip Bioventures II LLC
- Applicants: Antecip Bioventures II LLC
- Inventors: Herriot Tabuteau
- Web page: https://patentgrep.com/patent/US10117880B2

## CPC

- A61K 31/663: Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/2004: {Excipients; Inactive ingredients}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid form or a salt form can be used to treat or alleviate pain or related conditions, such as allodynia associated with complex regional pain syndrome.

## Claims

### Claim 1

A method of treating severe pain associated with complex regional pain syndrome, comprising administering a parenteral dose of 5 mg to 500 mg of neridronic acid, in a salt form or an acid form, to a human being suffering from severe pain associated with complex regional pain syndrome, wherein the human being has a pain score of at least about 7 on the 0-10 numeric rating scale.

### Claim 2 (depends on 1)

The method of claim 1, wherein the parenteral dose is administered in divided doses of about 10 mg to about 150 mg of the neridronic acid.

### Claim 3 (depends on 1)

The method of claim 1, wherein the human being is suffering from complex regional pain syndrome type I.

### Claim 4 (depends on 1)

The method of claim 1, wherein the human being is suffering from complex regional pain syndrome type II.

### Claim 5

A method of treating hyperalgesia associated with complex regional pain syndrome, comprising administering a parenteral dose of 5 mg to 500 mg of neridronic acid, in a salt form or an acid form, to a human being suffering from hyperalgesia associated with complex regional pain syndrome.

### Claim 6 (depends on 5)

The method of claim 5, wherein the parenteral dose is administered in divided doses of about 10 mg to about 150 mg of the neridronic acid.

### Claim 7 (depends on 5)

The method of claim 5, wherein the human being is suffering from complex regional pain syndrome type I.

### Claim 8 (depends on 5)

The method of claim 5, wherein the human being is suffering from complex regional pain syndrome type II.

### Claim 9

A method of treating allodynia associated with complex regional pain syndrome, comprising administering a parenteral dose of 5 mg to 500 mg of neridronic acid, in a salt form or an acid form, to a human being suffering from allodynia associated with complex regional pain syndrome.

### Claim 10 (depends on 9)

The method of claim 9, wherein the parenteral dose is administered in divided doses of about 10 mg to about 150 mg of the neridronic acid.

### Claim 11 (depends on 9)

The method of claim 9, wherein the human being is suffering from complex regional pain syndrome type I.

### Claim 12 (depends on 9)

The method of claim 9, wherein the human being is suffering from complex regional pain syndrome type II.

### Claim 13

A method of treating edema associated with complex regional pain syndrome, comprising administering a parenteral dose of 5 mg to 500 mg of neridronic acid, in a salt form or an acid form, to a human being suffering from edema associated with complex regional pain syndrome.

### Claim 14 (depends on 13)

The method of claim 13, wherein the parenteral dose is administered in divided doses of about 10 mg to about 150 mg of the neridronic acid.

### Claim 15 (depends on 13)

The method of claim 13, wherein the human being is suffering from complex regional pain syndrome type I.

### Claim 16 (depends on 13)

The method of claim 13, wherein the human being is suffering from complex regional pain syndrome type II.